<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1010211109
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Glucophage XR
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METFORMIN HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Prolonged-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        33.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MERCK HEALTHCARE KGAA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MERCK HEALTHCARE KGAA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SERONO EUROPE LTD
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Glucophage XR prolonged release tablets contain the active ingredient metformin hydrochloride and belong to a group of medicines called biguanides, used in the treatment of Type 2 (non-insulin dependent) diabetes mellitus.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Glucophage XR is used together with diet and exercise to lower the risk of developing Type 2 diabetes in overweight adults, when diet and exercise alone for 3 to 6 months have not been enough to control blood glucose (sugar).&nbsp; You are at high risk of developing Type 2 diabetes if you have additional conditions like high blood pressure, age above 40 years, an abnormal amount of lipids (fat) in the blood or a history of diabetes during pregnancy.</p><p dir="ltr">The medicine is particularly effective if you are aged below 45 years, are very overweight, have high blood glucose levels after a meal or developed diabetes during pregnancy.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Glucophage XR is used for the treatment of Type 2 diabetes when diet and exercise changes alone have not been enough to control blood glucose (sugar). Insulin is a hormone that enables body tissues to take glucose from the blood and to use it for energy or for storage for future use.&nbsp; People with Type 2 diabetes do not make enough insulin in their pancreas or their body does not respond properly to the insulin it does make. This causes a build-up of glucose in the blood which can cause a number of serious long-term problems so it is important that you continue to take your medicine, even though you may not have any obvious symptoms. Glucophage XR makes the body more sensitive to insulin and helps return to normal the way your body uses glucose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Glucophage XR is associated with either a stable body weight or modest weight loss.</p><p dir="ltr">Glucophage XR Prolonged Release Tablets are specially made to release the drug slowly in your body and therefore are different to many other types of tablet containing metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Glucophage </strong>XR <strong>if:</strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to metformin or to any of the other ingredients of this medicine (listed in section 6). An allergic reaction may cause a rash, itching or shortness of breath.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have liver problems</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have severely reduced kidney function</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have uncontrolled diabetes, with, for example, severe hyperglycemia (high blood glucose), nausea, vomiting, diarrhea, rapid weight loss, lactic acidosis (see &lsquo;Risk of lactic acidosis&rsquo; below) or ketoacidosis. Ketoacidosis is a condition in which substances&nbsp; called &lsquo;ketone bodies&rsquo; accumulate in the blood and which can lead to diabetic pre-coma. Symptoms include stomach pain, fast and deep breathing, sleepiness or your breath developing an unusual, fruity smell.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have lost too much water from your body (dehydration). Dehydration may lead to kidney problems, which can put you at risk for lactic acidosis (see &#39;Warnings and precautions&rsquo;).</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a severe infection, such as an infection affecting your lung or bronchial system or your kidney. Severe infections may lead to kidney problems, which can put you at risk for lactic acidosis (see &#39;Warnings and precautions&rsquo;).</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have been treated for acute heart problems or have recently had a heart attack or have severe circulatory problems or breathing difficulties. This may lead to a lack in oxygen supply to tissue which can put you at risk for lactic acidosis (see &#39;Warnings and precautions&rsquo;).</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are a heavy drinker of alcohol.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are under 18 years of age.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Warnings and precautions</p><p dir="ltr"><strong><u>Risk of lactic acidosis</u></strong></p><p dir="ltr">Glucophage XR may cause a very rare, but very serious side effect called lactic acidosis, particularly if your kidneys are not working properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration (see further information below), liver problems and any medical conditions in which a part of the body has a reduced supply of oxygen (such as acute severe heart disease).</p><p dir="ltr">If any of the above apply to you, talk to your doctor for further instructions.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Stop taking Glucophage XR for a short time if you have a condition that may be associated with dehydration </strong>(significant loss of body fluids) such as severe vomiting, diarrhea, fever, exposure to heat or if you drink less fluid than normal. Talk to your doctor for further instructions.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Stop taking Glucophage XR and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis</strong>, as this condition may lead to coma.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Symptoms of lactic acidosis include: ▪ vomiting</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ▪ &nbsp;&nbsp;&nbsp; stomach ache (abdominal pain)</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ▪ &nbsp;&nbsp;&nbsp; muscle cramps</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ▪ &nbsp;&nbsp;&nbsp; a general feeling of not being well with severe tiredness</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ▪ &nbsp;&nbsp;&nbsp; difficulty in breathing</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ▪ &nbsp;&nbsp;&nbsp; reduced body temperature and heartbeat</p><p dir="ltr">&nbsp;</p><p dir="ltr">Lactic acidosis is a medical emergency and must be treated in a hospital.</p><p dir="ltr">If you need to have major surgery, you must stop taking Glucophage XR during and for some time after the procedure. Your doctor will decide when you must stop and when to restart your treatment with Glucophage XR.</p><p dir="ltr">&nbsp;</p><p dir="ltr">During treatment with Glucophage XR, your doctor will check your kidney function at least once a year or more frequently if you are elderly and/or if you have worsening kidney function.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you are older than 75 years, treatment with Glucophage XR should not be started to lower the risk of developing type 2 diabetes.</p><p dir="ltr">&nbsp;</p><p dir="ltr">You may see some remains of the tablets in your stools. Do not worry - this is normal for this type of tablet.</p><p dir="ltr">You should continue to follow any dietary advice that your doctor has given you and you should make sure that you eat carbohydrates regularly throughout the day. Do not stop taking this medicine without speaking to your doctor.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Other medicines and Glucophage XR</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">If you need to have an injection of a contrast medium that contains iodine into your bloodstream, in the context of an X-ray or scan, you must stop taking Glucophage XR before or at the time of injection. Your doctor will decide when you must stop and when to restart your treatment with Glucophage XR.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Tell your doctor if you are taking, have recently taken or might take any other medicines. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dosage of Glucophage XR. It is especially important to mention the following:</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines which increase urine production (diuretics (water tablets) such as furosemide).</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to&nbsp; treat&nbsp; pain&nbsp; and&nbsp; inflammation&nbsp; (NSAID&nbsp; and&nbsp; COX-2&nbsp; inhibitors,&nbsp; such&nbsp; as ibuprofen and celecoxib)</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain medicines for the treatment of high blood pressure (ACE inhibitors and angiotensin II receptor antagonists)</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steroids such as prednisolone, mometasone, beclomethasone.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sympathomimetic medicines including epinephrine and dopamine used to treat heart attacks and low blood pressure.&nbsp; Epinephrine is also included in some dental anesthetics.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that may change the amount of Glucophage XR in your blood, especially if you have reduced kidney function (such as verapamil, rifampicin, cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, crizotinib, olaparib).</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Glucophage XR with alcohol:</strong></p><p dir="ltr">Avoid excessive alcohol intake while taking Glucophage XR since this may increase the risk of lactic acidosis (see section &lsquo;Warnings and precautions&rsquo;).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Pregnancy and breast-feeding</p><p dir="ltr">Do not take Glucophage XR if you are pregnant or breast feeding.</p><p dir="ltr">Ask your doctor or pharmacist for advice before taking any medicine.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Driving and using machines</p><p dir="ltr">Glucophage XR taken on its own does not cause &lsquo;hypos&rsquo; (symptoms of low blood sugar or hypoglycemia, such as faintness, confusion and increased sweating) and therefore should not affect your ability to drive or use machinery.</p><p dir="ltr">You should be aware, however, that Glucophage XR taken with other antidiabetic medicines can cause hypos, so in this case you should take extra care when driving or operating machinery.</p><p>&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Your doctor may prescribe Glucophage XR for you to take on its own, or in combination with other oral antidiabetic medicines or insulin.</p><p dir="ltr">Always take Glucophage XR exactly as your doctor has told you.</p><p dir="ltr">You should check with your doctor or pharmacist if you are not sure. Swallow the tablets whole with a glass of water, do not chew.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Recommended dose</u></p><p dir="ltr">Usually you will start treatment with 500 milligrams Glucophage XR daily. After you have been taking Glucophage XR for about 2 weeks, your doctor may measure your blood sugar and adjust the dose. The maximum daily dose is 2000 milligrams of Glucophage XR. If you have reduced kidney function, your doctor may prescribe a lower dose.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Normally, you should take the tablets once a day, with your evening meal.</p><p dir="ltr">In some cases, your doctor may recommend that you take the tablets twice a day. Always take the tablets with food.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you take more Glucophage XR than you should</p><p dir="ltr">If you take extra tablets by mistake you need not worry, but if you have unusual symptoms, contact your doctor. If the overdose is large, lactic acidosis is more likely.&nbsp; Symptoms of lactic acidosis are non-specific, such as vomiting, bellyache with muscle cramps, a general feeling of not being well with severe tiredness, and difficulty in breathing.&nbsp; Further symptoms are reduced body temperature and heartbeat.&nbsp; If you experience some of these symptoms, you should immediately seek medical attention, as lactic acidosis may lead to coma. Stop taking Glucophage XR immediately and contact a doctor or the nearest hospital straightaway.</p><p dir="ltr">&nbsp;</p><p dir="ltr">If you forget to take Glucophage XR</p><p dir="ltr">Take it as soon as you remember with some food. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, Glucophage XR can cause side effects, although not everybody gets them.&nbsp; The following side effects may occur:</p><p dir="ltr">Glucophage XR may cause a very rare (may affect up to 1 user in 10,000) but very serious side effect called lactic acidosis (see section &lsquo;Warnings and Precautions&rsquo;). If this happens, you must <strong>stop taking Glucophage </strong>XR <strong>and contact a doctor or the nearest hospital immediately</strong>, as lactic acidosis may lead to coma.</p><p dir="ltr">Glucophage XR may cause abnormal liver function tests and hepatitis (inflammation of the liver) which may result in jaundice (may affect up to 1 user in 10,000). If you develop yellowing of the eyes and/or skin contact your doctor immediately.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Other possible side effects are listed by frequency as follows:</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Very common (affects more than 1 person in 10):</em></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhea, nausea, vomiting, stomach ache or loss of appetite. If you get these, do not stop taking the tablets as these symptoms will normally go away in about 2 weeks. It helps if you take the tablets with or immediately after a meal.</p><p dir="ltr"><em>Common (affects less than 1 person in 10, but more than 1 person in 100):</em></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taste disturbance</p><p dir="ltr"><em>Very rare (affects less than 1 person in 10,000):</em></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased vitamin B12 levels</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rashes including redness, itching and hives.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store Below 30 &deg;C</p><p dir="ltr">Keep Glucophage XR tablets out of the sight and reach of children.</p><p dir="ltr">Do not use them after the expiry date that is printed on the pack after &ldquo;EXP:&rdquo;. The expiry date refers to the last day of that month.</p><p dir="ltr">This medicinal product does not require any special storage conditions.</p><p dir="ltr">Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Each prolonged release tablet contains 500, 750 or 1000 milligrams of the active ingredient metformin hydrochloride. The other ingredients are magnesium stearate, Carmellose sodium and Hypromellose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The 500 milligram tablets are white to off -white and round with ‘500’ on one side. 
The 750 milligram tablets are white to off -white and capsule-shaped with ‘750’ on one side and 
‘MERCK’ on the other side. 
The 1000 milligrams tablets are white to off-white and capsule-shaped with ‘1000’ on one side and 
‘MERCK’ on the other side. 
Glucophage XR is supplied in packs of 30 prolonged release tablets. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Marketing Authorization Holder &nbsp;</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Merck Serono Ltd,</p><p dir="ltr">5 New Square,</p><p dir="ltr">Bedfont Lakes Business Park,</p><p dir="ltr">Felltham, Middlesex, TW14 8HA</p><p dir="ltr">United Kingdom</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Manufacturer </strong></p><p dir="ltr">&nbsp;</p><p dir="ltr">Merck Sant&eacute; s.a.s, 2 rue du Pressoir Vert, 45400 Semoy, France.</p><p dir="ltr">or</p><p dir="ltr">Merck Healthcare KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in Feb 2020 
 

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي أقراص جلوكوفاج إكس آر الممتدة المفعول على المادة الفعالة ميتفورمين هيدروكلوريد وتنتمي إلى مجموعة من الأدوية تسمى البيجوانيد، وتستخدم في علاج مرض السكري من النوع 2 (غير المعتمد على الأنسولين).</p><p>&nbsp;</p><p dir="RTL">يستخدم جلوكوفاج إكس آر مع نظام غذائي وتمارين رياضية لخفض خطر الإصابة بالنوع الثاني من مرض السكري عند البالغين الذين يعانون من زيادة الوزن، حين يكون الالتزام باتباع نظام غذائي وتمارين رياضية فقط لمدة تتراوح بين 3 إلى 6 أشهر غير كافِ للسيطرة على نسبة الجلوكوز في الدم (السكر).&nbsp; أنت معرض لخطر الإصابة بمرض السكري من النوع 2 بشكل كبير إذا كنت تعاني من حالات مرضيَة أخرى مثل ارتفاع ضغط الدم، أو إذا كان عمرك فوق 40 عامًا، أو كانت كمية الدهون (الشحوم) في الدم غير طبيعية أو لديكِ تاريخ إصابة بمرض السكري أثناء الحمل.</p><p dir="RTL">هذا الدواء فعال بشكل خاص إذا كان عمرك أقل من 45 عامًا، أو تعاني من زيادة الوزن، أو ارتفاع مستويات السكر في الدم بعد تناول وجبة أو إذا كنتِ مصابة بمرض السكري أثناء الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم جلوكوفاج إكس آر لعلاج مرض السكري من النوع 2 عندما تكون التغييرات في النظام الغذائي والتمارين الرياضية وحدها غير كافية للسيطرة على نسبة الجلوكوز في الدم (السكر). الأنسولين هو هرمون يمكّن أنسجة الجسم من امتصاص الجلوكوز من الدم واستخدامه لإنتاج الطاقة أو تخزينها لاستخدامها في المستقبل.&nbsp; ولا ينتج الجسم في حالة المرضى بمرض السكري من النوع 2 كمية كافية من الأنسولين في البنكرياس أو لا يستجيب بطريقة صحيحة للإنسولين الذي ينتجه. وهو ما يؤدي إلى تراكم الجلوكوز في الدم والذي يمكن أن يسبب عددًا من المشاكل الخطيرة طويلة الأمد، لذلك يجب الاستمرار في تناول الدواء، حتى وإن لم تظهر عليك أي أعراض واضحة. ويجعل جلوكوفاج إكس آر الجسم أكثر حساسية للأنسولين ويساعده في العودة إلى استخدام الجلوكوز بطريقة طبيعية.</p><p>&nbsp;</p><p dir="RTL">يرتبط جلوكوفاج إكس آر إما بثبات وزن الجسم أو بخسارة بسيطة في الوزن.</p><p dir="RTL">وصُممت أقراص جلوكوفاج إكس آر الممتدة المفعول لإطلاق الدواء في الجسم ببطء وبالتالي فإنها تختلف عن أنواع أخرى كثيرة من الأقراص التي تحتوي على الميتفورمين.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول جلوكوفاج إكس آر إذا:</strong><strong> </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك حساسية تجاه الميتروفين أو أيٍ من المكونات الأخرى لهذا الدواء (المذكورة في القسم رقم 6). قد يسبب تفاعل الحساسية حدوث طفح جلدي، أو حكة، أو ضيق في التنفس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشاكل في الكبد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من قصور شديد في وظائف الكلى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مرض السكري الذي لا يمكن السيطرة عليه، على سبيل المثال، ارتفاع السكر في الدم (جلوكوز الدم المرتفع) والغثيان والقيء والإسهال وفقدان الوزن السريع، الحماض اللاكتيكي (انظر &quot;مخاطر الحماض اللاكتيكي&quot; أدناه) أو الحماض الكيتوني. الحماض الكيتوني هو حالة مرضيَة تتراكم فيها المواد المسماة &quot;الأجسام الكيتونية&quot; في الدم والتي قد تؤدي إلى مقدمات الغيبوبة السكرية. تشمل الأعراض ألم في المعدة، أو التنفس السريع والعميق، أو النعاس، أو ظهور رائحة فاكهة غير طبيعية في النفس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدت الكثير من الماء من الجسم (الجفاف). قد يؤدي الجفاف إلى مشكلات في الكلى، مما قد يعرضك لخطر الإصابة بالحماض اللاكتيكي (انظر &quot;التحذيرات والاحتياطات&quot;).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك عدوى حادة، مثل العدوى التي تؤثر على الرئة، أو الشعب الهوائية، أو الكلى. قد تؤدي حالات العدوى إلى مشكلات في الكلى، مما قد يعرضك لخطر الإصابة بالحماض اللاكتيكي (انظر &quot;التحذيرات والاحتياطات&quot;).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد خضعت للعلاج من مشاكل قلبية حادة، أو تعرضت مؤخرًا لأزمة قلبية، أو لديك مشكلات في الدورة الدموية أو صعوبات في التنفس. قد يؤدي ذلك إلى نقص في وصول الأكسجين للأنسجة مما قد يعرضك لخطر الإصابة بالحماض اللاكتيكي (انظر &quot;التحذيرات والاحتياطات&quot;).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول الكحول بكميات مفرطة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت أقل من 18 عامًا.</p><p>&nbsp;</p><p>التحذيرات والاحتياطات</p><p dir="RTL"><strong><u>مخاطر الحماض اللاكتيكي</u></strong></p><p dir="RTL">قد يتسبب جلوكوفاج إكس آر في حدوث أثر جانبي نادر جدًا، ولكنه خطير جدًا يسمى الحماض اللاكتيكي، خاصة إذا كانت الكليتان لا تعملان بشكل صحيح. يزداد خطر الإصابة بالحماض اللاكتيكي أيضًا بسبب مرض السكري غير المتحكم فيه، أو حالات العدوى الخطيرة، أو الصيام لفترة طويلة، أو تناول الكحول، أو الجفاف (انظر مزيد من المعلومات أدناه)، أو مشاكل في الكبد أو أي حالات طبية يكون فيها جزء من الجسم يعاني من نقص في إمداد الأكسجين (مثل مرض القلب الحاد الشديد).</p><p dir="RTL">إذا كان أي مما سبق ينطبق عليك، فاستشر طبيبك لمزيد من التعليمات.</p><p>&nbsp;</p><p dir="RTL"><strong>توقف عن تناول جلوكوفاج إكس آر لفترة قصيرة إذا كنت تعاني من حالة مرضية قد تكون مرتبطة بالجفاف </strong>(فقدان شديد لسوائل الجسم) مثل القيء الشديد، أو الإسهال، أو الحمى أو التعرض للحرارة، أو إذا كنت تتناول كميات سوائل أقل من المعتاد. استشر طبيبك لمزيد من التعليمات.</p><p>&nbsp;</p><p dir="RTL"><strong>توقف عن تناول جلوكوفاج إكس آر واتصل بالطبيب أو أقرب مستشفى على الفور إذا شعرت ببعض أعراض الحماض اللاكتيكي،</strong> لأن هذه الحالة المرضيَة قد تؤدي إلى غيبوبة.</p><p>&nbsp;</p><p dir="RTL">تشمل أعراض الحماض اللاكتيكي:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في المعدة (آلام في البطن)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنّجات العضلية</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور عام بأنك لست على ما يرام مع التعب الشديد</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض درجة حرارة الجسم ونبضات القلب</p><p>&nbsp;</p><p dir="RTL">يُعد الحُماض اللاكتيكي حالة طبية طارئة ويجب علاجها في المستشفى.</p><p dir="RTL">إذا كنت بحاجة إلى الخضوع لعملية جراحية كبيرة، فيجب عليك التوقف عن تناول جلوكوفاج إكس آر أثناء العملية ولبعض الوقت بعد العملية. سيقرر طبيبك متى يجب أن تتوقف ومتى تستأنف علاجك بالجلوكوفاج إكس آر.</p><p>&nbsp;</p><p dir="RTL">أثناء العلاج باستخدام جلوكوفاج إكس آر، سيقوم الطبيب بفحص وظائف الكلى على الأقل مرة واحدة في العام أو أكثر إذا كنت من كبار السن أو إذا كنت تعاني من تدهور وظائف الكلى.</p><p dir="RTL">إذا كان عمرك أكبر من 75 عامًا، فيجب ألا تبدأ العلاج بجلوكوفاج إكس آر لتقليل خطر تطور الإصابة بالنوع الثاني من مرض السكري.</p><p>&nbsp;</p><p dir="RTL">قد ترى بعض بقايا الأقراص في البراز. لا تقلق - فهذا طبيعي مع هذا النوع من الأقراص.</p><p dir="RTL">يجب مواصلة الالتزام بأي نصيحة غذائية قدمها لك طبيبك وعليك التأكد من تناول الكربوهيدرات بانتظام طوال اليوم. لا تتوقف عن تناول هذا الدواء دون استشارة طبيبك.</p><p>&nbsp;</p><p>الأدوية الأخرى وجلوكوفاج إكس آر</p><p><strong>&nbsp;</strong></p><p dir="RTL">إذا كنت بحاجة إلى حقن وسيط تباين يحتوي على اليود في مجرى الدم، على سبيل المثال، عند الحاجة لإجراء الأشعة السينية أو المسح الضوئي، فيجب عليك التوقف عن تناول جلوكوفاج إكس آر قبل وقت الحقن أو أثنائه. وسيقرر طبيبك متى يجب أن تتوقف ومتى تستأنف علاجك بالجلوكوفاج إكس آر.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أدوية أخرى أو تناولتها مؤخرًا أو ربما تتناولها في المستقبل. قد يكون من الضروري إجراء تحليل الجلوكوز في الدم واختبارات وظائف الكلى بشكل متكرر، أو قد يحتاج طبيبك إلى تعديل جرعة جلوكوفاج إكس آر. ومن الضروري ذكر ما يلي تحديدًا:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تزيد من إنتاج البول (مدرات البول (أقراص الماء) مثل فوروسيميد).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج الألم والالتهابات (مثبطات مضادات الالتهاب غير الستيروئيدية وكوكس-2، مثل إيبوبروفين وسيليكوكسيب)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية معينة لعلاج ارتفاع ضغط الدم (مثبطات الإنزيم المحول للأنغيوتنسين ومضادات مستقبلات الأنغيوتنسين 2)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستيرويدات مثل بريدنيزولون، وموميتازون، وبيكلوميثاسون.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية محاكي الودي بما في ذلك الإيبينيفرين والدوبامين المستخدمة لعلاج النوبات القلبية وانخفاض ضغط الدم.&nbsp; والإبِينيفرِين مدرج أيضًا في بعض مواد التخدير السني.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تغير كمية جلوكوفاج إكس آر في الدم، وخاصة إذا كنت تعاني من قصور في وظائف الكلى (مثل فيراباميل، ريفامبيسين، سيميتيدين، دولوتيجرافير، رانولازين، تريميثوبريم، فانديتانيب، إيزافوكونازول، كريزوتينيب، أولاباريب).</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>جلوكوفاج إكس آر والمشروبات الكحولية:</strong></p><p dir="RTL">تجنب الإفراط في تناول المشروبات الكحولية أثناء تناول جلوكوفاج إكس آر لأن ذلك قد يزيد من خطر الإصابة بالحماض اللاكتيكي (انظر قسم &quot;التحذيرات والاحتياطات&quot;).</p><p>&nbsp;</p><p>الحمل والإرضاع الطبيعي</p><p dir="RTL">لا تتناولي جلوكوفاج إكس إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية.</p><p dir="RTL">استشري طبيبك أو الصيدلي قبل تناول أي دواء.</p><p>&nbsp;</p><p>القيادة واستعمال الآلات</p><p dir="RTL">جلوكوفاج إكس آر الذي يتم تناوله بمفرده لا يسبب &quot;نقص في سكر الدم&quot; (أعراض نقص السكر في الدم، مثل الإغماء، وتشوش الذهن، وزيادة التعرق) وبالتالي يجب ألا يؤثر على قدرتك على القيادة أو استخدام الآلات.</p><p dir="RTL">ومع ذلك، يجب أن تدرك أن جلوكوفاج إكس آر الذي يتم تناوله مع أدوية أخرى لعلاج مرض السكري يمكن أن يسبب انخفاضًا في نسبة السكر، لذا يجب في هذه الحالة أن تتوخى الحذر عند القيادة أو تشغيل الآلات.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يصف لك الطبيب تناول جلوكوفاج إكس آر بمفرده، أو مع أدوية أخرى لعلاج مرض السكري، أو الأنسولين.</p><p dir="RTL">تناول دائمًا جلوكوفاج إكس آر وفقًا لتوجيهات الطبيب تمامًا.</p><p dir="RTL">استشر طبيبك أو الصيدلي إذا كنت غير متأكد من استخدامه. ابتلع القرص كاملًا بكوب من الماء، ولا تمضغه.</p><p>&nbsp;</p><p dir="RTL"><u>الجرعة الموصى بها</u></p><p dir="RTL">يبدأ العلاج عادة بجرعة 500 ملليغرام يوميًا من جلوكوفاج إكس آر. بعد تناول جلوكوفاج إكس آر لمدة أسبوعين تقريبًا، يمكن لطبيبك قياس نسبة السكر في الدم وتعديل الجرعة. الجرعة اليومية القصوى هي 2000 ملليغرام من جلوكوفاج إكس آر. إذا كنت تعاني من قصور في وظائف الكلى، فقد يصف لك الطبيب جرعة أقل.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">عادة، يجب أن تأخذ الأقراص مرة واحدة يوميًا، مع وجبة المساء.</p><p dir="RTL">في بعض الحالات، قد يوصي طبيبك بتناول الأقراص مرتين في اليوم. تناول الأقراص دائمًا مع الطعام.</p><p>&nbsp;</p><p>إذا تناولت كمية أكبر ممّا يجب من جلوكوفاج إكس آر</p><p dir="RTL">إذا تناولت أقراصًا إضافية عن طريق الخطأ، فلا داعي للقلق، ولكن إذا شعرت بأعراض غير عادية، فاتصل بطبيبك. إذا كانت الجرعة الزائدة كبيرة، فقد تزداد احتمالية حدوث الحماض اللاكتيكي.&nbsp; أعراض الحماض اللاكتيكي غير محددة، مثل القيء، وألم في البطن، وتشنجات العضلات، والشعور العام بأنك لست على ما يرام مع التعب الشديد، وصعوبة التنفس.&nbsp; تشمل الأعراض الأخرى انخفاض درجة حرارة الجسم ونبضات القلب.&nbsp; إذا ظهرت عليك بعضًا من هذه الأعراض، فيجب عليك طلب الرعاية الطبية على الفور، لأن الحماض اللاكتيكي قد يؤدي إلى غيبوبة. توقف عن تناول جلوكوفاج إكس آر على الفور واتصل بالطبيب أو أقرب مستشفى على الفور.</p><p>&nbsp;</p><p>إذا نسيت تناول جرعة جلوكوفاج إكس آر</p><p dir="RTL">فتناولها بمجرد تذكرها مع بعض الطعام. لا تتناول جرعة مضاعفة لتعويض جرعة فاتتك.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن كل الأدوية، قد يسبب جلوكوفاج إكس آر آثارًا جانبية ولكن ليس لجميع الأشخاص الذين يتناولونه.&nbsp; قد تحدث الآثار الجانبية التالية:</p><p dir="RTL">قد يتسبب جلوكوفاج إكس آر في حدوث أثر جانبي نادر جدًا (قد يصيب ما يصل إلى مريض واحد في 10000)، ولكن خطير جدًا يسمى الحماض اللاكتيكي (انظر قسم &quot;التحذيرات والاحتياطات&quot;). إذا حدث ذلك، يجب <strong>التوقف عن تناول جلوكوفاج </strong>إكس آر <strong>والاتصال بالطبيب أو أقرب مستشفى على الفور</strong>، لأن الحماض اللاكتيكي قد يؤدي إلى غيبوبة.</p><p dir="RTL">جلوكوفاج إكس آر قد يجعل نتائج اختبارات وظائف الكبد غير طبيعية وقد يسبب التهاب الكبد الذي قد يؤدي إلى اليرقان (قد يؤثر على ما يصل إلى مريض واحد من بين كل 10000 شخص). إذا كنت تعاني من اصفرار العينين أو الجلد، فاتصل بطبيبك على الفور.</p><p>&nbsp;</p><p dir="RTL">الآثار الجانبية الأخرى المحتملة مدرجة حسب معدل تكرار حدوثها على النحو التالي:</p><p>&nbsp;</p><p dir="RTL"><strong><em>شائعة جدًا (قد تصيب أكثر من </em></strong><strong><em>1</em></strong><strong><em> من بين كل </em></strong><strong><em>10</em></strong><strong><em> أشخاص):</em></strong><strong> </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال، أو الغثيان، أو القيء، أو آلام المعدة، أو فقدان الشهية. إذا ظهرت عليك هذه الأعراض، فلا تتوقف عن تناول الأقراص لأن هذه الأعراض ستختفي عادةً في حوالي أسبوعين. يُنصح بتناول الأقراص مع الوجبة أو بعدها مباشرة.</p><p dir="RTL"><strong><em>شائعة (قد تصيب أقل من </em></strong><strong><em>1</em></strong><strong><em> من بين كل </em></strong><strong><em>10</em></strong><strong><em> أشخاص، ولكن أكثر من </em></strong><strong><em>1</em></strong><strong><em> من بين كل </em></strong><strong><em>100</em></strong><strong><em> شخص):</em></strong><strong><em> </em></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في التذوق</p><p dir="RTL"><strong><em>نادرة جدًا (تصيب أقل من </em></strong><strong><em>1</em></strong><strong><em> من بين كل </em></strong><strong><em>10000</em></strong><strong><em> شخص):</em></strong><strong> </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات فيتامين ب 12</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي بما في ذلك الاحمرار، والحكة، والشرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفَظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ جلوكوفاج إكس آر بعيدًا عن متناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم الأقراص بعد تاريخ انتهاء الصلاحية المطبوع على العبوة بعد الاختصار &quot;EXP:&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذا المنتج الطبي لا يتطلب أي ظروف تخزين خاصة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم التخلص من الأدوية عن طريق إلقائها في مياه الصرف أو النفايات المنزلية. اسأل الصيدلي عن الطريقة الصحيحة للتخلص من الأدوية التي لم تعد في حاجة إليها. تساعد هذه التدابير على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحتوي كل قرص ممتد المفعول على 750، أو 1000 ملغ على المادة الفعالة ميتفورمين هيدروكلوريد.</p><p dir="RTL">المكونات الأخرى هي ستيرات المغنيسيوم، وكارميلوز الصوديوم، وهيبروميلوز.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شكل جلوكوفاج إكس آر ومحتويات العلبة:</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص 500 ميليغرام من الأبيض إلى الأبيض الباهت ومستديرة مع &quot;500&quot; على جانب واحد.</p><p dir="RTL">أقراص 750 ملغ بيضاء أو مائلة للون الأبيض، على شكل كبسولة، منقوش على أحد جانبيها &quot;750&quot;</p><p dir="RTL">ومنقوش على الجانب الآخر كلمة &quot;MERCK&quot;.</p><p dir="RTL">أقراص 1000 ملغ، بيضاء أو شبه بيضاء اللون، على شكل كبسولة، منقوش على أحد جانبيها &quot;1000&quot;.</p><p dir="RTL">ومنقوش على الجانب الآخر كلمة &quot;MERCK&quot;.</p><p dir="RTL">يتوفر جلوكوفاج إكس آر في علب تحتوي على 30 قرصًا ممتد المفعول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL"><strong>حامل رخصة التسويق</strong></p><p>&nbsp;</p><p dir="RTL">ميرك سيرونو المحدودة،</p><p dir="RTL">5 ساحة جديدة,</p><p dir="RTL">حديقة بيدفونت للبحيرات التجارية,</p><p dir="RTL">فيثام، ميدلسبره، TW14 8HA</p><p dir="RTL">المملكة المتحدة</p><p>&nbsp;</p><p dir="RTL"><strong>جهة التصنيع</strong></p><p>&nbsp;</p><p>شركة میرك سانتي</p><p>2 شارع دو بریسوار فیرت ،</p><p>، Semoy 45400</p><p dir="RTL">سیموي ، فرنسا</p><p dir="RTL">&nbsp;</p><p dir="RTL">أو &nbsp;</p><p>میرك هيلث كير كي جي اي</p><p>فرانكفورتر شتراسھ 250</p><p>&nbsp;64293 دارمشتات</p><p>ألمانیا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر مراجعة لهذه النشرة كانت في: فبراير 2020  
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Glucophage XR 1000 mg prolonged release tablet 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One prolonged release tablet contains 1000 mg metformin hydrochloride corresponding to 780 mg metformin base. 
For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Prolonged release tablet 
White to off-white capsule-shaped, biconvex tablet, debossed on one side with '1000' and on the other side with 'MERCK'. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">&bull; Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with IGT* and/or IFG*, and/or increased HbA1C who are:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp; at high risk for developing overt type 2 diabetes mellitus (see section 5.1) and</p><p dir="ltr">-&nbsp;&nbsp;&nbsp; still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months</p><p dir="ltr">Treatment with Glucophage XR must be based on a risk score incorporating appropriate measures of glycemic control and including evidence of high cardiovascular risk (see section 5.1).</p><p dir="ltr">Lifestyle modifications should be continued when metformin is initiated, unless the patient is unable to do so because of medical reasons.</p><p dir="ltr">*IGT: Impaired Glucose Tolerance; IFG: Impaired Fasting Glucose</p><p dir="ltr">&bull; Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycemic control. Glucophage XR may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><em>Adults with normal renal function (GFR&ge; 90 mL/min) </em></p><p dir="ltr"><em>Reduction in the risk or delay of the onset of type 2 diabetes</em></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metformin should only be considered where intensive lifestyle modifications for 3 to 6 months have not resulted in adequate glycemic control.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The therapy should be initiated with one tablet Glucophage XR 500 mg once daily with the evening meal.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After 10 to 15 days dose adjustment on the basis of blood glucose measurements is recommended (OGTT and/or FPG and/or HbA1c values to be within the normal range). A slow increase of dose may improve gastro-intestinal tolerability. The maximum recommended dose of Glucophage XR 1000 mg is 2 tablets (2000 mg) once daily with the evening meal.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is recommended to regularly monitor (every 3-6 months) the glycemic status (OGTT and/or FPG and/or HbA1c value) as well as the risk factors to evaluate whether treatment needs to be continued, modified or discontinued.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A decision to re-evaluate therapy is also required if the patient subsequently implements improvements to diet and/or exercise, or if changes to the medical condition will allow increased lifestyle interventions to be possible.</p><p dir="ltr"><em>Monotherapy in Type 2 diabetes mellitus and combination with other oral antidiabetic agents:</em></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glucophage XR 1000 mg should be taken once daily with the evening meal at a maximum recommended dose of 2 tablets per day.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glucophage XR 1000 mg is intended as a maintenance therapy for patients currently treated with either 1000 mg or 2000 mg of metformin hydrochloride. On switch, the daily dose of Glucophage XR should be equivalent to the current daily dose of metformin hydrochloride.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients treated with metformin hydrochloride at a dose above 2000 mg daily, switching to Glucophage XR is not recommended.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients new to metformin hydrochloride, the usual starting dose of Glucophage XR is 500 mg once daily given with the evening meal. After 10 to 15 days the dose should be adjusted on the basis of blood glucose measurements. A slow increment in dose may improve gastrointestinal tolerability.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If glycemic control is not achieved on once daily dosing of Glucophage XR at a maximum dose of 2000 mg a day, then a twice daily dosing schedule should be considered with both doses being given with food, at the time of the morning and evening meals. If glycemic control is still not achieved, patients may be switched to standard metformin hydrochloride tablets to a maximum dose of 3000 mg daily.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the event of transfer from another oral antidiabetic agent, titration should begin with Glucophage XR 500 mg before switching to Glucophage XR 1000 mg as indicated above.</p><p dir="ltr"><em>Combination with insulin:</em></p><p dir="ltr">Metformin hydrochloride and insulin may be used in combination therapy to achieve better blood glucose control. The usual starting dose of Glucophage XR is 500 mg once daily with the evening meal, while insulin dosage is adjusted on the basis of blood glucose measurements. After titration, switch to Glucophage SR 1000 mg should be considered.</p><p dir="ltr"><em>Elderly:</em></p><p dir="ltr">Due to the potential for decreased renal function in elderly subjects, the metformin hydrochloride dosage should be adjusted based on renal function. Regular assessment of renal function is necessary (see section 4.4).</p><p dir="ltr">Benefit in the reduction of risk or delay of the onset of type 2 diabetes mellitus has not been established in patients 75 years and older (see section 5.1) and metformin initiation is therefore not recommended in these patients (see section 4.4).</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Renal impairment</em></p><p dir="ltr">&nbsp;</p><p dir="ltr">A GFR should be assessed before initiation of treatment with metformin containing products and at least annually thereafter. In patients at an increased risk of further progression of renal impairment and in the elderly, renal function should be assessed more frequently, e.g. every 3-6 months.</p><p dir="ltr">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr" style="width:603px"><tbody><tr><td style="vertical-align:top"><p>GFR</p><p>(mL/min)</p></td><td style="vertical-align:top"><p>Total maximum daily dose</p></td><td style="vertical-align:top"><p>Additional considerations</p></td></tr><tr><td style="vertical-align:top"><p>60-89</p></td><td style="vertical-align:top"><p>2000 mg</p></td><td style="vertical-align:top"><p>Dose reduction may be considered in relation to declining renal function.</p></td></tr><tr><td style="vertical-align:top"><p>45-59</p></td><td style="vertical-align:top"><p>2000 mg</p></td><td rowspan="2" style="vertical-align:top"><p>Factors that may increase the risk of lactic acidosis (see section 4.4) should be reviewed before considering initiation of metformin. The starting dose is at most half of the maximum dose.</p></td></tr><tr><td style="vertical-align:top"><p>30-44</p></td><td style="vertical-align:top"><p>1000 mg</p></td></tr><tr><td style="vertical-align:top"><p>&lt;30</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Metformin is contraindicated.</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Pediatric population</em>:</p><p dir="ltr">&nbsp;</p><p dir="ltr">In the absence of available data, Glucophage XR should not be used in children.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to metformin or to any of the excipients listed in section 6.1. 
•	Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis) 
•	Diabetic pre-coma 
•	Severe renal failure (GFR < 30 mL/min). 
•	Acute conditions with the potential to alter renal function such as: 
-	dehydration, - 	severe infection, - 	shock. 
•	Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as: 
-	decompensated heart failure, 
-	respiratory failure, - 	recent myocardial infarction, 
-	shock. 
•	Hepatic insufficiency, acute alcohol intoxication, alcoholism 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Lactic acidosis:</strong></p><p dir="ltr">Lactic acidosis, a very rare, but serious, metabolic complication, most often occurs at acute worsening of renal function or cardiorespiratory illness or sepsis.&nbsp; Metformin accumulation occurs at acute worsening of renal function and increases the risk of lactic acidosis.</p><p dir="ltr">In case of dehydration (severe diarrhea or vomiting, fever or reduced fluid intake), metformin should be temporarily discontinued and contact with a health care professional is recommended.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and NSAIDs) should be initiated with caution in metformin-treated patients. Other risk factors for lactic acidosis are excessive alcohol intake, hepatic insufficiency, inadequately controlled diabetes, ketosis, prolonged fasting and any conditions associated with hypoxia, as well as concomitant use of medicinal products that may cause lactic acidosis (see sections 4.3 and 4.5).</p><p dir="ltr">Patients and/or care-givers should be informed of the risk of lactic acidosis. Lactic acidosis is characterized by acidotic dyspnea, abdominal pain, muscle cramps, asthenia and hypothermia followed by coma. In case of suspected symptoms, the patient should stop taking metformin and seek immediate medical attention. Diagnostic laboratory findings are decreased blood pH (&lt; 7.35), increased plasma lactate levels (&gt;5 mmol/L) and an increased anion gap and lactate/pyruvate ratio.</p><p dir="ltr"><strong><u>Renal function</u>:</strong></p><p dir="ltr">GFR should be assessed before treatment initiation and regularly thereafter, see section 4.2. Metformin is contraindicated in patients with GFR&lt;30 mL/min and should be temporarily discontinued in the presence of conditions that alter renal function, see section 4.3.</p><p dir="ltr"><strong><u>Cardiac function:</u></strong></p><p dir="ltr">Patients with heart failure are more at risk of hypoxia and renal insufficiency. In patients with stable chronic heart failure, metformin may be used with a regular monitoring of cardiac and renal function.</p><p dir="ltr">For patients with acute and unstable heart failure, metformin is contraindicated (see section 4.3).</p><p dir="ltr"><strong>Elderly:</strong></p><p dir="ltr">Due to the limited therapeutic efficacy data in the reduction of risk or delay of type 2 diabetes in patients 75 years and older, metformin initiation is not recommended in these patients.</p><p dir="ltr"><strong><u>Administration of iodinated contrast agents</u>:</strong></p><p dir="ltr">Intravascular administration of iodinated contrast agents may lead to contrast induced nephropathy, resulting in metformin accumulation and an increased risk of lactic acidosis. Metformin should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.5.</p><p dir="ltr"><strong><u>Surgery</u>:</strong></p><p dir="ltr">Metformin must be discontinued at the time of surgery under general, spinal or epidural anesthesia. Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and provided that renal function has been re-evaluated and found to be stable.</p><p dir="ltr"><strong><u>Other precautions:</u></strong></p><p dir="ltr">All patients should continue their diet with a regular distribution of carbohydrate intake during the day. Overweight patients should continue their energy-restricted diet.</p><p dir="ltr">The usual laboratory tests for diabetes monitoring should be performed regularly. Metformin alone never causes hypoglycemia, although caution is advised when it is used in combination with insulin or other oral antidiabetics (e.g. Sulphonylureas or meglitinides).</p><p dir="ltr">The tablet shells may be present in the faeces. Patients should be advised that this is normal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Concomitant use not recommended</u></strong></p><p dir="ltr"><em>Alcohol</em></p><p dir="ltr">Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in case of fasting, malnutrition or hepatic impairment.</p><p dir="ltr"><em>Iodinated contrast agents</em></p><p dir="ltr">Metformin must be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.4.</p><p dir="ltr"><strong><u>Combinations requiring precautions for use</u></strong></p><p dir="ltr">Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics. When starting or using such products in combination with metformin, close monitoring of renal function is necessary.</p><p dir="ltr"><em>Medicinal products with intrinsic hyperglycemic activity (e.g. glucocorticoids (systemic and local routes) and sympathomimetics).</em></p><p dir="ltr">More frequent blood glucose monitoring may be required, especially at the beginning of treatment. If necessary, adjust the metformin dosage during therapy with the other drug and upon its discontinuation.</p><p dir="ltr"><em>Organic cation transporters (OCT)</em></p><p dir="ltr">Metformin is a substrate of both transporters OCT1 and OCT2.</p><p dir="ltr">Co-administration of metformin with</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Inhibitors of OCT1 (such as verapamil) may reduce efficacy of metformin.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy of metformin.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Inhibitors of OCT2 (such as cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole) may decrease the renal elimination of metformin and thus lead to an increase in metformin plasma concentration.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp; Inhibitors of both OCT1 and OCT2 (such as crizotinib, olaparib) may alter efficacy and renal elimination of metformin.</p><p dir="ltr">Caution is therefore advised, especially in patients with renal impairment, when these drugs are co- administered with metformin, as metformin plasma concentration may increase. If needed, dose adjustment of metformin may be considered as OCT inhibitors/inducers may alter the efficacy of metformin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Pregnancy</u></p><p dir="ltr">Uncontrolled diabetes during pregnancy (gestational or permanent) is associated with increased risk of congenital abnormalities and perinatal mortality.</p><p dir="ltr">A limited amount of data from the use of metformin in pregnant women does not indicate an increased risk of congenital abnormalities. Animal studies do not indicate harmful effects with respect to pregnancy, embryonic or fetal development, parturition or postnatal development (see section 5.3). When the patient plans to become pregnant and during pregnancy, it is recommended that impaired glycemic control or diabetes are not treated with metformin.&nbsp; For diabetes it is recommended that insulin should be used to maintain blood glucose levels as close to normal as possible to reduce the risk of malformations of the fetus.</p><p dir="ltr"><u>Breast-feeding</u></p><p dir="ltr">Metformin is excreted into human breast milk. No adverse effects were observed in breastfed newborns/infants. However, as only limited data are available, breastfeeding is not recommended during metformin treatment. A decision on whether to discontinue breast-feeding should be made, taking into account the benefit of breast-feeding and the potential risk to adverse effect on the child.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Fertility</u></p><p dir="ltr">Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately three times the maximum recommended human daily dose based on body surface area comparisons.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Metformin monotherapy does not cause hypoglycemia and therefore has no effect on the ability to drive or to use machines.</p><p dir="ltr">However, patients should be alerted to the risk of hypoglycemia when metformin is used in combination with other antidiabetic agents (e.g. Sulphonylureas, insulin, or meglitinides).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">In post marketing data and in controlled clinical studies, adverse event reporting in patients treated with Glucophage XR was similar in nature and severity to that reported in patients treated with Glucophage immediate release.</p><p dir="ltr">&nbsp;</p><p dir="ltr">During treatment initiation, the most common adverse reactions are nausea, vomiting, diarrhea, abdominal pain and loss of appetite, which resolve spontaneously in most cases.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The following adverse reactions may occur with Glucophage XR.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Frequencies are defined as follows: very common: &gt;1/10; common <u>&gt;</u>1/100, &lt;1/10; uncommon <u>&gt;</u>1/1,000, &lt;1/100; rare <u>&gt;</u>1/10,000, &lt;1/1,000; very rare &lt;1/10,000.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. <u>Metabolism and nutrition disorders</u></p><p dir="ltr"><em>Very rare</em>:</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lactic acidosis (see 4.4. Special warnings and precautions for use).</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease of vitamin B12 absorption with decrease of serum levels during long-term use of metformin.&nbsp; Consideration of such an aetiology is recommended if a patient presents with megaloblastic anemia.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Nervous system disorders</u></p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Common</em></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taste disturbance</p><p dir="ltr"><u>Gastrointestinal disorders</u></p><p dir="ltr"><em>Very common:</em></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrointestinal disorders such as nausea, vomiting, diarrhea, abdominal pain and loss of appetite. These undesirable effects occur most frequently during initiation of therapy and resolve spontaneously in most cases. A slow increase of the dose may also improve gastrointestinal tolerability.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Hepatobiliary disorders</u></p><p dir="ltr"><em>Very rare:</em></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Isolated reports of liver function tests abnormalities or hepatitis resolving upon metformin discontinuation.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Skin and subcutaneous tissue disorders</u></p><p dir="ltr">&nbsp;</p><p dir="ltr"><em>Very rare:</em></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin reactions such as erythema, pruritus, urticaria</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">To report any side effect(s):</p><ul dir="ltr"><li><strong><em>Saudi Arabia: </em></strong></li></ul><p dir="ltr">&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>- The National Pharmacovigilance Centre (NPC)</p><ul><li>Fax: +966-11-205-7662</li><li>Toll free phone: 8002490000</li><li>E-mail: npc.drug@sfda.gov.sa &nbsp;</li><li>Website: https://ade.sfda.gov.sa/</li></ul><p>&nbsp;</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">&middot;&nbsp;&nbsp; Other GCC States:</p><p dir="ltr">&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p dir="ltr">&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Hypoglycemia has not been seen with metformin hydrochloride doses of up to 85 g, although lactic acidosis has occurred in such circumstances. High overdose or concomitant risks of metformin hydrochloride may lead to lactic acidosis. Lactic acidosis is a medical emergency and must be treated in hospital. The most effective method to remove lactate and metformin is hemodialysis.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">ORAL ANTI-DIABETICS</p><p dir="ltr">(A10BA02: Gastrointestinal tract and metabolism)</p><p dir="ltr">Metformin hydrochloride is a biguanide with antihyperglycemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycemia.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Mechanism of action</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Metformin hydrochloride may act via 3 mechanisms:</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis &bull; &nbsp; in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilization</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and delay of intestinal glucose absorption.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Metformin hydrochloride stimulates intracellular glycogen synthesis by acting on glycogen synthase. Metformin hydrochloride increases the transport capacity of all types of membrane glucose transporters (GLUT).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Pharmacodynamic effects</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">In clinical studies, the major non glycemic effect of metformin is either weight stability or modest weight loss.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In humans, independently of its action on glycaemia, immediate release metformin hydrochloride has favorable effects on lipid metabolism. This has been shown at therapeutic doses in controlled, medium-term or long-term clinical studies: immediate release metformin hydrochloride reduces total cholesterol, LDL cholesterol and triglyceride levels. A similar action has not been demonstrated with the prolonged release formulation, possibly due to the evening administration, and an increase in triglycerides may occur.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Clinical efficacy:</u></p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Reduction in the risk or delay of type 2 diabetes mellitus</u></em></p><p dir="ltr"><strong><em>&nbsp;</em></strong></p><p dir="ltr">The <strong>Diabetes Prevention Program </strong>(DPP) was a multicenter randomized controlled clinical trial in adults assessing the efficacy of an intensive lifestyle intervention or metformin to prevent or delay the development of type 2 diabetes mellitus.&nbsp; Inclusion criteria were age &ge;25 years, BMI &ge;24 kg/m<sup>2 </sup>(&ge;22 kg/m<sup>2 </sup>for Asian-Americans), and impaired glucose tolerance plus a fasting plasma glucose of 95 &ndash; 125 mg/dl (or &le;125 mg/dl for American Indians).&nbsp;&nbsp; Patients were either treated with intensive lifestyle intervention, 2x850 mg metformin plus standard lifestyle change, or placebo plus standard lifestyle change.</p><p dir="ltr">The mean baseline values of the DPP participants (n=3,234 for 2.8 years) were age 50.6&plusmn;10.7 years, 106.5&plusmn;8.3mg/dl fasted plasma glucose, 164.6&plusmn;17.0mg/dl plasma glucose two hours after an oral glucose load, and 34.0&plusmn;6.7kg/m<sup>2 </sup>BMI.&nbsp; Intensive lifestyle intervention as well as metformin significantly reduced the risk of developing overt diabetes compared to placebo, 58% (95% CI 48- 66%) and 31% (95% CI 17-43%), respectively.</p><p dir="ltr">The advantage of the lifestyle intervention over metformin was greater in older persons.</p><p dir="ltr">&nbsp;</p><p dir="ltr">The patients who benefited most from the metformin treatment were aged below 45 years, with a BMI equal or above 35kg/m<sup>2</sup>, a baseline glucose 2 h value of 9.6-11.0 mmol/l, a baseline HbA1C equal or above 6.0% or with a history of gestational diabetes.</p><p dir="ltr">&nbsp;</p><p dir="ltr">To prevent one case of overt diabetes during the three years in the whole population of the DPP, 6.9 patients had to participate in the intensive lifestyle group and 13.9 in the metformin group. The point of reaching a cumulative incidence of diabetes equal to 50% was delayed by about three years in the metformin group compared to placebo.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">The <strong>Diabetes Prevention Program Outcomes Study </strong>(DPPOS) is the long-term follow-up study of the DPP including more than 87% of the original DPP population for long-term follow up.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Among the DPPOS participants (n=2776), the cumulative incidence of diabetes at year 15 is 62% in the placebo group, 56% in the metformin group, and 55% in the intensive lifestyle intervention group.</p><p dir="ltr">Crude rates of diabetes are 7.0, 5.7 and 5.2 cases per 100 person‐years among the placebo, metformin, and intensive lifestyle participants, respectively. Reductions in the diabetes risk were of 18% (hazard ratio (HR) 0.82, 95% CI 0.72&ndash;0.93; p=0.001) for the metformin group and 27% (HR 0.73, 95% CI 0.65&ndash;0.83; p&lt;0.0001) for the intensive lifestyle intervention group, when compared with the placebo group. For an aggregate microvascular endpoint of nephropathy, retinopathy and neuropathy the outcome was not significantly different between the treatment groups, but, among the participants who had not developed diabetes during DPP/DPPOS, the prevalence of the aggregate microvascular outcome was 28% lower compared with those who had developed diabetes (Risk Ratio 0.72, 95% CI 0.63&ndash;0.83; p&lt;0.0001). No prospective comparative data for metformin on macrovascular outcomes in patients with IGT and/or IFG and/or increased HbA1c is available.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Published risk factors for type 2 diabetes include: Asian or black ethnic background, age above 40, dyslipidemia, hypertension, obesity or being overweight, age, 1st degree family history of diabetes, history of gestational diabetes mellitus, and polycystic ovary syndrome (PCOS).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Consideration must be given to current national guidance on the definition of prediabetes.</p><p dir="ltr">Patients at high risk should be identified by a validated risk-assessment tool.</p><p dir="ltr"><em><u>Treatment of type 2 diabetes mellitus</u></em></p><p dir="ltr"><strong><em>&nbsp;</em></strong></p><p dir="ltr">The prospective randomized (UKPDS) study has established the long-term benefit of intensive blood glucose control in overweight type 2 diabetic patients treated with immediate release metformin hydrochloride as first-line therapy after diet failure. Analysis of the results for overweight patients treated with metformin hydrochloride after failure of diet alone showed:</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a significant reduction of the absolute risk of any diabetes-related complication in the metformin hydrochloride group (29.8 events/ 1000 patient-years) versus diet alone (43.3 events/ 1000 patient- years), p=0.0023, and versus the combined Sulphonylureas and insulin monotherapy groups (40.1 events/ 1000 patient-years), p=0.0034.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a significant reduction of the absolute risk of diabetes-related mortality: metformin hydrochloride 7.5 events/1000 patient-years, diet alone 12.7 events/ 1000 patient-years, p=0.017;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a significant reduction of the absolute risk of overall mortality: metformin hydrochloride 13.5 events/ 1000 patient-years versus diet alone 20.6 events/ 1000 patient-years (p=0.011), and versus the combined Sulphonylureas and insulin monotherapy groups 18.9 events/ 1000 patient- years (p=0.021);</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a significant reduction in the absolute risk of myocardial infarction: metformin hydrochloride 11 events/ 1000 patient-years, diet alone 18 events/ 1000 patient-years (p=0.01)</p><p dir="ltr">&nbsp;</p><p dir="ltr">For metformin hydrochloride used as second-line therapy, in combination with a Sulphonylureas, benefit regarding clinical outcome has not been shown.</p><p dir="ltr">&nbsp;</p><p dir="ltr">In type 1 diabetes, the combination of metformin hydrochloride and insulin has been used in selected patients, but the clinical benefit of this combination has not been formally established.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Following a single oral administration in the fed state of one tablet of Glucophage XR 1000 mg, a mean peak plasma concentration of 1214 ng/ml is achieved with a median time of 5 hours (range of 4</p><p dir="ltr">to 10 hours).</p><p dir="ltr">Glucophage XR 1000 mg was shown to be bioequivalent to Glucophage XR 500 mg at a 1000 mg dose with respect to C<sub>max </sub>and AUC in healthy fed and fasted subjects.</p><p dir="ltr">The bioequivalent product shows the following properties:</p><p dir="ltr">At steady state, similar to the immediate release formulation, C<sub>max </sub>and AUC are not proportionally increased to the administered dose. The AUC after a single oral administration of 2000 mg of metformin hydrochloride prolonged release tablets is similar to that observed after administration of 1000 mg of metformin hydrochloride immediate release tablets b.i.d.</p><p dir="ltr">Intrasubject variability of C<sub>max </sub>and AUC of metformin hydrochloride prolonged release tablets is comparable to that observed with metformin hydrochloride immediate release tablets.</p><p dir="ltr">When the 1000 mg prolonged release tablet is administered in fed conditions the AUC is increased by</p><p dir="ltr">77% (C<sub>max </sub>is increased by 26% and T<sub>max </sub>is slightly prolonged by about 1 hour).</p><p dir="ltr">Mean metformin hydrochloride absorption from the prolonged release formulation is almost not altered by meal composition.</p><p dir="ltr">No accumulation is observed after repeated administration of up to 2000 mg of metformin hydrochloride prolonged release tablets.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Distribution</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Plasma protein binding is negligible. Metformin partitions into erythrocytes. The blood peak is lower than the plasma peak and appears at approximately the same time. The red blood cells most likely represent a secondary compartment of distribution. The mean volume of distribution (Vd) ranged between 63-276 l.</p><p dir="ltr"><u>Metabolism</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Metformin is excreted unchanged in the urine. No metabolites have been identified in humans.</p><p dir="ltr"><u>Elimination</u></p><p dir="ltr">Renal clearance of metformin is &gt; 400 ml/min, indicating that metformin is eliminated by glomerular filtration and tubular secretion. Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 hours.</p><p dir="ltr">When renal function is impaired, renal clearance is decreased in proportion to that of creatinine and thus the elimination half-life is prolonged, leading to increased levels of metformin in plasma.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Characteristics in specific groups of patients</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Renal impairment</p><p dir="ltr">&nbsp;</p><p dir="ltr">The available data in subjects with moderate renal insufficiency are scarce and no reliable estimation of the systemic exposure to metformin in this subgroup as compared to subjects with normal renal function could be made. Therefore, the dose adaptation should be made upon clinical efficacy/tolerability considerations (see section 4.2).</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Preclinical data reveal no special hazard for humans based on conventional studies on safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity reproduction</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Carmellose sodium 50.00 mg</p><p dir="ltr">Hypromellose 392.300 mg &nbsp;</p><p dir="ltr">Magnesium stearate 7.00 mg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store Below 30 &deg;C</p><p dir="ltr">This medicinal product does not require any special storage conditions.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">14, 20, 28, 30, 50, 56, 60, 84, 90, 100, 112, 120, 180 or 600 tablets in blister strips composed of aluminum foil + PVC/PVDC 90g/m&sup2;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No special requirements.</p><p dir="ltr">Any unused product or waste material should be disposed of in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Merck Serono Ltd  
5 New Square 
Bedfont Lakes Business Park 
Felltham 
Middlesex  
TW14 8HA UK

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 25 February 2020 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>